US Patent

US11986527 — Pharmaceutical formulations containing corticosteroids for topical administration

Method of Use · Assigned to Bausch Health Ireland Ltd · Expires 2031-11-02 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical formulations containing corticosteroids for topical administration.

USPTO Abstract

Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

Drugs covered by this patent

halobetasol-propionate (HALOBETASOL PROPIONATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2625`	—	halobetasol-propionate
`U-2625`	—

Patent Metadata

Patent number: US11986527
Jurisdiction: US
Classification: Method of Use
Expires: 2031-11-02
Drug substance claim: No
Drug product claim: No
Assignee: Bausch Health Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.